Head-to-head · WeighScore
FuturHealth vs RxSaludable
The verdict
FuturHealth takes it — 65.6/100 to 63.2/100.
FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | RxSaludable |
|---|---|---|
| WeighScore | 65.6/100 | 63.2/100 |
| Grade | C | C |
| Scorecard rank | #215 | #259 |
| Semaglutide | $199/mo (compounded) | $179/mo (compounded) |
| Tirzepatide | Not disclosed | $269/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #259 · C
Strengths
- Spanish-language platform with Spanish-speaking, U.S.-licensed providers — a genuine gap in GLP-1 telehealth
- Compounded semaglutide $99 first month ($179/mo after) and tirzepatide $189 first month; same price at every dose, no membership fee
- LegitScript-certified (#50274281); free expedited shipping; named obesity-medicine physicians
- Same-day doctor visits, 24/7 support, FSA/HSA eligible, cancel anytime
Where it loses points
- Ongoing prices ($179-289/mo) are mid-range once the first-month intro ends
- Doesn't name its compounding pharmacy partners (generic 'certified pharmacies')
- No legal entity name or explicit state-coverage list published on the site
- Compounded GLP-1s are not FDA-approved (the site discloses this)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.